SpringWorks Therapeutics, Inc. Share Price

Equities

SWTX

US85205L1070

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 16:01:15 14/06/2024 BST 5-day change 1st Jan Change
38.18 USD -2.44% Intraday chart for SpringWorks Therapeutics, Inc. -5.22% +4.44%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 139M 11.01B Sales 2025 * 318M 25.12B Capitalization 2.9B 229B
Net income 2024 * -334M -26.38B Net income 2025 * -241M -19.04B EV / Sales 2024 * 19.9 x
Net cash position 2024 * 123M 9.73B Net cash position 2025 * 399M 31.51B EV / Sales 2025 * 7.86 x
P/E ratio 2024 *
-8.5 x
P/E ratio 2025 *
-11.2 x
Employees 305
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.5%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : SpringWorks Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM
SpringWorks Therapeutics, Inc. Receive Notice of Termination of the Amended and Restated Collaboration and License Agreement with GlaxoSmithKline Intellectual Property Development Ltd CI
Springworks Therapeutics Insider Sold Shares Worth $801,372, According to a Recent SEC Filing MT
Springworks Therapeutics Insider Sold Shares Worth $1,955,113, According to a Recent SEC Filing MT
SpringWorks Therapeutics, Inc. Announces Data to Be Presented at the 2024 American Society of Clinical Oncology Annual Meeting CI
Transcript : SpringWorks Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
Wedbush Raises SpringWorks Therapeutics' Price Target to $75 From $70, Keeps Outperform Rating MT
SpringWorks Therapeutics Shares Fall After Wider-Than-Expected Q1 Loss MT
Transcript : SpringWorks Therapeutics, Inc., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q1 Revenue $21M, vs. Street Est of $13.1M MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment MT
More news
1 day-2.32%
1 week-5.22%
Current month-8.06%
1 month-11.25%
3 months-22.96%
6 months+9.92%
Current year+4.44%
More quotes
1 week
37.77
Extreme 37.77
40.57
1 month
37.62
Extreme 37.62
45.81
Current year
35.66
Extreme 35.66
53.92
1 year
18.00
Extreme 18
53.92
3 years
13.60
Extreme 13.6
89.75
5 years
13.60
Extreme 13.6
96.48
10 years
13.60
Extreme 13.6
96.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 31/07/17
Chairman 65 31/12/15
Director of Finance/CFO 64 31/07/19
Members of the board TitleAgeSince
Director/Board Member 67 31/07/19
Director/Board Member 69 31/07/17
Director/Board Member 61 13/07/22
More insiders
Date Price Change Volume
14/06/24 38.12 -2.61% 42 313
13/06/24 39.14 +0.77% 468,149
12/06/24 38.84 -0.21% 831,556
11/06/24 38.92 -2.63% 931,765
10/06/24 39.97 -0.62% 701,074

Delayed Quote Nasdaq, June 14, 2024 at 03:45 pm

More quotes
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
39.14 USD
Average target price
65.92 USD
Spread / Average Target
+68.42%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW